Deepali Sachdev, PhD

Dr. Deepali Sachdev, Ph.D., is an Assistant Professor in the Department of Medicine at the University of Minnesota and a member of the Breast Cancer Program at the University of Minnesota Cancer Center.  She received her Ph.D. from the University of Texas Health Science Center at San Antonio.  She holds memberships in the American Association for Cancer Research and the Endocrine Society.  

Her research interests focus on the regulation of breast cancer biology by growth factors such as insulin-like growth factors, growth factor targeted therapy for breast cancer, and development of biomarkers for growth factor targeted therapy.  Her laboratory is examining the use of non-invasive magnetic resonance imaging and spectroscopy and gene array signatures to predict and monitor response to inhibition of insulin-like growth factor signaling in breast cancer cell growth and metastasis.  She is also examining the mechanisms by which insulin-like growth factors regulate metastasis of breast cancer cells using animal models of metastasis and in vivo imaging. 

Selected Publications 

Sachdev D, Chirgwin JM.  Solubility of proteins isolated from inclusion bodies is enhanced by fusion to maltose-binding protein or thioredoxin.  Protein Exp Purif. 12:122-132, 1998. 

Sachdev D, Chirgwin JM.  Order of fusions between mammalian and bacterial proteins can determine solubility in Escherichia coli.  Biochem Biophys Res Commun. 244:933-937, 1998. 

Sachdev D, Chirgwin JM.  Epitope mapping of recombinant human procathepsin D.  Advan  Experimental Med and Biol. 436:185-189, 1998. 

Chirgwin JM, Schultz S, Sachdev D.  Expression of chimeric human aspartic proteinases.  Advan  Experimental Med and Biol. 436:139-146, 1998. 

Sachdev D, Chirgwin JM.  Properties of soluble fusions between mammalian aspartic proteinases and bacterial maltose-binding protein.  J Protein Chem. 18:127-136, 1999. 

Sachdev D, Chirgwin JM.  Fusions to maltose-binding protein to control folding and solubility.  Methods Enzymol. 326:312-21, 2000. 

Sachdev D, Yee D.  The IGF system and breast cancer.  Endocr Relat Cancer. 8:197-209, 2001. 

Lee AV, Schiff R, Cui X, Sachdev D, Yee D, Gilmore AP, Streuli CH, Oesterreich S, Hadsell DL.  New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation.  Clin Cancer Res. 9:516S-23S, 2003. 

Sachdev D, Li S, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D.  A chimeric humanized single-chain antibody against the type I insulin-like growth factor receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.  Cancer Res. 63:627-35, 2003.

Ye J, Liang S, Guo N, Li S, Wu AM, Giannini S, Sachdev D, Yee D, Brunner N, Ikle D, Fujita-Yamaguchi, Y.  Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo.  Horm Metab Res. 35:836-842, 2003. 

Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D.  A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.  J Biol Chem. 279(6):5017-24, 2004. 

Zhang X, Kamaraju S, Hakuno F, Kabuta T, Takahashi S, Sachdev D, Yee D.  Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression.  Breast Cancer Res Treat. 83:161-170, 2004.

Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D.  Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implications for anti-insulin-like growth factor therapy in breast cancer.  Cancer Res. 66:2391-402, 2006.

Sachdev D, Yee D.  Inhibitors of insulin-like growth factor signaling: A therapeutic approach for breast cancer.  J Mammary Gland Biol and Neoplasia. 11:27-39, 2006.

Sachdev D, Yee D.  Disrupting insulin-like growth factor signaling as a potential cancer therapy.  Mol Cancer Ther. 6:1-12, 2007.